Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 5, 2012, Pages 459-466

  De Silva, P S A ^a   Nguyen, D D ^a   Sauk, J ^a   Korzenik, J ^a   Yajnik, V ^a   Ananthakrishnan, A N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEMALE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONONEUROPATHY; NEUROPATHY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84864714487     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05214.x     Document Type: Article

References (19)

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Sandborn WJ, Feagan BG, Stoinov S, et al,. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
4. Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
5. Billioud V, Sandborn WJ, Peyrin-Biroulet L,. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84.
6. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
7. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
8. Sandborn WJ, Abreu MT, D'Haens G, et al,. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: e2.
9. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
10. D'Haens G, Baert F, van Assche G, et al,. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
11. Sandborn WJ, Colombel JF, Enns R, et al,. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25.
12. Yousry TA, Major EO, Ryschkewitsch C, et al,. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-33.
13. Allez M, Vermeire S, Mozziconacci N, et al,. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101.
14. Virkki LM, Valleala H, Takakubo Y, et al,. Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011; 30: 1447-54.
15. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al,. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
16. Colombel JF, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
17. Meier J, Sturm A,. Concomitant use of immunomodulators with anti-TNF in Crohn's disease: yes or no? Curr Drug Targets 2010; 11: 176-8.
18. Lichtenstein GR, Diamond RH, Wagner CL, et al,. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
19. Ananthakrishnan AN, Hur C, Korzenik JR,. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 2011; 57: 472-80.